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BACKGROUND
In sub-Saharan Africa, the burden of human immunodeficiency virus (HIV)–associ-
ated tuberculosis is high. We conducted a trial with a 2-by-2 factorial design to 
assess the benefits of early antiretroviral therapy (ART), 6-month isoniazid preven-
tive therapy (IPT), or both among HIV-infected adults with high CD4+ cell counts 
in Ivory Coast.
METHODS
We included participants who had HIV type 1 infection and a CD4+ count of less 
than 800 cells per cubic millimeter and who met no criteria for starting ART ac-
cording to World Health Organization (WHO) guidelines. Participants were ran-
domly assigned to one of four treatment groups: deferred ART (ART initiation 
according to WHO criteria), deferred ART plus IPT, early ART (immediate ART 
initiation), or early ART plus IPT. The primary end point was a composite of dis-
eases included in the case definition of the acquired immunodeficiency syndrome 
(AIDS), non–AIDS-defining cancer, non–AIDS-defining invasive bacterial disease, 
or death from any cause at 30 months. We used Cox proportional models to com-
pare outcomes between the deferred-ART and early-ART strategies and between 
the IPT and no-IPT strategies.
RESULTS
A total of 2056 patients (41% with a baseline CD4+ count of ≥500 cells per cubic 
millimeter) were followed for 4757 patient-years. A total of 204 primary end-point 
events were observed (3.8 events per 100 person-years; 95% confidence interval 
[CI], 3.3 to 4.4), including 68 in patients with a baseline CD4+ count of at least 
500 cells per cubic millimeter (3.2 events per 100 person-years; 95% CI, 2.4 to 4.0). 
Tuberculosis and invasive bacterial diseases accounted for 42% and 27% of pri-
mary end-point events, respectively. The risk of death or severe HIV-related illness 
was lower with early ART than with deferred ART (adjusted hazard ratio, 0.56; 95% 
CI, 0.41 to 0.76; adjusted hazard ratio among patients with a baseline CD4+ count 
of ≥500 cells per cubic millimeter, 0.56; 95% CI, 0.33 to 0.94) and lower with IPT 
than with no IPT (adjusted hazard ratio, 0.65; 95% CI, 0.48 to 0.88; adjusted haz-
ard ratio among patients with a baseline CD4+ count of ≥500 cells per cubic mil-
limeter, 0.61; 95% CI, 0.36 to 1.01). The 30-month probability of grade 3 or 4 
adverse events did not differ significantly among the strategies.
CONCLUSIONS
In this African country, immediate ART and 6 months of IPT independently led to 
lower rates of severe illness than did deferred ART and no IPT, both overall and 
among patients with CD4+ counts of at least 500 cells per cubic millimeter. 
(Funded by the French National Agency for Research on AIDS and Viral Hepatitis; 
TEMPRANO ANRS 12136 ClinicalTrials.gov number, NCT00495651.)
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The recommended CD4+ count threshold for starting antiretroviral thera-py (ART) in asymptomatic human immu-
nodeficiency virus (HIV)–infected adults in low-
er-resource countries was increased from 200 
cells per cubic millimeter in 2006 to 500 cells 
per cubic millimeter in 2013.1,2 This change was 
supported by the results of two randomized, 
controlled trials.3,4
Meanwhile, three types of arguments have 
emerged to support even earlier initiation of 
ART. First, there is increasing documentation of 
inflammation in people with uncontrolled viral 
replication and of non–acquired immunodefi-
ciency syndrome (AIDS)–defining noninfectious 
diseases as causes of death in HIV-infected per-
sons5,6 (with AIDS-defining diseases identified 
as diseases included in the Centers for Disease 
Control and Prevention case definition of AIDS7). 
Second, among patients living with HIV in low-
er-resource countries, the rates of tuberculosis 
and bacterial diseases are high. These infectious 
diseases are both common and opportunistic, 
meaning that their incidence is high in the gen-
eral population, higher among HIV-infected pa-
tients with high CD4+ cell counts, and extreme-
ly high among patients with low CD4+ cell 
counts.8,9 They have consistently been shown to 
be major causes of death among HIV-infected 
patients in settings where access to diagnosis 
and treatment is low.10-16 These diseases trig-
gered the question “Should we start ART earli-
er?” in low-income countries.17
Third, ART has been shown to be effective in 
reducing the risk of HIV transmission.3 This 
observation led to the hypothesis that recom-
mending all HIV-infected persons to start ART 
irrespective of their CD4+ count might help curb 
the epidemic.18 This public health argument, 
however, is acceptable only if earlier ART leads 
to a favorable benefit–risk ratio at the individual 
level.
Here we present the results of a trial that as-
sessed the efficacy of early ART in reducing the 
rate of severe illness among HIV-infected adults 
in Ivory Coast. Because tuberculosis was ex-
pected to be an important target for early ART 
in this African country, the benefit of combining 
isoniazid preventive therapy (IPT) with early 
ART was assessed in the same trial, with the use 
of a factorial design. In Ivory Coast, the national 
guidelines do not recommend the use of IPT, 
owing to the concern that IPT may select resis-
tant bacilli when given to patients with undiag-
nosed tuberculosis.19,20 The Ministry of Health 
accepted its use within an experimental frame-
work.
Me thods
Study Design and Oversight
The TEMPRANO ANRS 12136 trial was an un-
blinded, multicenter, individual-randomized, 
controlled, 2-by-2 factorial, 1:1 superiority trial 
that was conducted at nine care centers in Abi-
djan, the economic capital of Ivory Coast. A de-
scription of the full study design is provided in 
the protocol and statistical analysis plan, avail-
able with the full text of this article at NEJM.org.
The protocol was approved by the Ivory Coast 
National Ethics Committee for Health Research. 
The sponsor (the French National Agency for 
Research on AIDS and Viral Hepatitis [ANRS]) 
had no role in the conduct of the study or the 
interpretation of the data.
Participants
Patients were eligible for inclusion in the study 
if they were 18 years of age or older, had HIV 
type 1 (HIV-1) infection or dual infection with 
HIV-1 and HIV-2, had a CD4+ count of less than 
800 cells per cubic millimeter, provided written 
informed consent, and met no criteria for start-
ing ART according to the most recent World 
Health Organization (WHO) guidelines. The lat-
ter included the absence of active tuberculosis, 
as determined with the use of a clinical algo-
rithm.21,22 No chest radiography was systemati-
cally performed before inclusion. The exclusion 
criteria are listed in Section 2 in the Supplemen-
tary Appendix, available at NEJM.org.
Randomization to Trial Groups  
and Strategies
A computer-generated, sequentially numbered, 
block randomization list, stratified according to 
study clinic, was drawn up and then included in 
a software tool that allowed access to the next 
available trial identification number and treat-
ment group. Participants were randomly as-
signed to one of four groups: group 1 (deferred 
ART), in which ART was deferred until WHO 
criteria for starting ART were met; group 2 (de-
ferred ART plus IPT), in which ART was deferred 
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until WHO criteria for starting ART were met 
and a 6-month course of IPT was started 1 
month after enrollment; group 3 (early ART), in 
which ART was started immediately; and group 
4 (early ART plus IPT), in which ART was started 
immediately and a 6-month course of IPT was 
started 1 month after enrollment. We will refer 
to trial groups each time we show separate data 
for each of the four groups and refer to trial 
strategies whenever we show data combining 
patients assigned to early ART (groups 3 and 4), 
deferred ART (groups 1 and 2), IPT (groups 2 
and 4), or no IPT (groups 1 and 3).
Baseline Tests
After the participants underwent randomization, 
plasma HIV-1 RNA was measured in all partici-
pants by means of a real-time polymerase-chain-
reaction assay (Generic HIV Charge Virale, Bio-
centric; threshold of detectability, 100 copies per 
milliliter), and systematic chest radiography was 
performed. The first 967 patients who under-
went randomization also underwent an interfer-
on-gamma release assay (IGRA) for tuberculosis 
(QuantiFERON-TB Gold test, Celestis). Other 
tests are listed in Section 2 in the Supplemen-
tary Appendix. All trial tests were performed in 
one reference laboratory. Tuberculin skin tests 
were not performed.
Trial Drugs
The first-line ART regimen consisted preferably 
of tenofovir–emtricitabine plus efavirenz. Pa-
tients with contraindications to efavirenz re-
ceived tenofovir–emtricitabine plus lopinavir–
ritonavir, or tenofovir–emtricitabine plus 
zidovudine. The latter regimen was abandoned 
in December 2008 owing to increased side ef-
fects in the upper digestive tract.23
IPT consisted of 300 mg of isoniazid daily, 
which was started 1 month after enrollment and 
stopped 7 months after enrollment. All the pa-
tients who were randomly assigned to groups 2 
and 4 were eligible for IPT irrespective of the 
results on IGRA for tuberculosis. However, pa-
tients who had images suggestive of active tu-
berculosis on their baseline chest radiograph, 
those who had aminotransferase levels greater 
than 2.5 times the upper limit of the normal 
range, and those in whom clinical signs sugges-
tive of tuberculosis developed during the first 
month after enrollment were not prescribed IPT.
Trimethoprim–sulfamethoxazole prophylaxis 
was prescribed in all patients who had a CD4+ 
count of less than 500 cells per cubic millimeter 
and no history of serious side effects from the 
drug. It was stopped when the CD4+ count rose 
above 500 cells per cubic millimeter.
Merck Sharp & Dohme donated Stocrin (efa-
virenz) and Gilead Sciences donated Truvada 
(tenofovir–emtricitabine) for all participants in 
the study; these companies had no other role in 
the study. Nouvelle Pharmacie de Santé Publique 
of Ivory Coast provided all other antiretroviral 
drugs, with support from the U.S. President’s 
Emergency Plan for AIDS Relief.
Evolution of Trial Procedures
The trial started in March 2008 and ended in 
January 2015. During this time period, the WHO 
guidelines for ART changed twice.1,2 The inclu-
sion criterion of “no WHO criteria for starting 
ART” and the criteria for starting ART in pa-
tients assigned to the deferred-ART strategy 
were thus updated over time in line with WHO 
guideline updates (Section 2 in the Supplemen-
tary Appendix).
End Points
Participants were followed for 30 months. Visits 
were scheduled monthly for 3 months and quar-
terly thereafter. CD4+ counts and plasma HIV-1 
RNA levels were measured every 6 months. 
Clinical events were reviewed by an event-docu-
mentation committee whose members were 
aware of the randomization assignments; events 
were classified as definite, probable, or possible 
according to standardized criteria (Sections 3 
and 4 in the Supplementary Appendix).
The primary end point was a composite of 
death from any cause, AIDS-defining disease, 
non–AIDS-defining cancer, or non–AIDS-defin-
ing invasive bacterial disease (Section 2 in the 
Supplementary Appendix). The main secondary 
end point was grade 3 or 4 illness, including all 
events with a grade of 3 or 4 according to the 
ANRS grading table (Section 5 in the Supple-
mentary Appendix). Other secondary end points 
were virologic suppression, which was assessed 
as the percentage of patients with an undetect-
able viral load, and adherence to treatment, as 
assessed by the medication possession ratio (the 
number of daily doses of antiretroviral drugs 
dispensed by the pharmacy to each patient, di-
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vided by that patient’s total follow-up time in 
days since the initiation of ART).24 Participants 
were considered to have completed IPT if they 
attended all six isoniazid prescription visits.
Statistical Analysis
We calculated that with 2076 participants en-
rolled, the study would have 80% power to de-
tect a 40% lower rate of the primary end point 
with a new strategy (early ART or IPT) than with 
the corresponding reference strategy (deferred 
ART or no IPT), assuming a 10% rate of the 
primary end point in the reference strategy and 
with correction factors to account for a 4.2% 
loss to follow-up (on the basis of previous stud-
ies) and for testing for interactions (Section 2 in 
the Supplementary Appendix). Main analyses 
were performed on an intention-to-treat basis.
For each trial group and strategy, we used the 
Kaplan–Meier method to estimate the cumula-
tive probability of the occurrence of an event and 
estimated rates by dividing the number of first 
events by the cumulative time at risk. Then, con-
sidering all groups together, we estimated 
CD4+-specific rates in the entire trial population 
by dividing the number of first events that oc-
curred during the time that patients had CD4+ 
counts within a given stratum by the cumulative 
time at risk spent in the stratum. Follow-up data 
were censored when participants were lost to 
follow-up before their 30-month visit (Section 2 
in the Supplementary Appendix).
Multivariate Cox proportional-hazards mod-
els were used to compare strategies with respect 
to event rates for the primary end point and its 
components and for the main secondary end 
point. Models systematically included three ex-
planatory variables: IPT status (yes vs. no), ART 
status (early vs. deferred), and trial center. Haz-
ard ratios were thus adjusted for the other strat-
egy and the trial center. Interaction between 
strategies was tested. The assumption of the 
proportional hazards was examined.
Prespecified sensitivity analyses were per-
formed to explore the influence of baseline 
CD4+ count and the robustness of the results 
with varying definitions of end points (Section 2 
in the Supplementary Appendix). All reported 
P values were two-sided and have not been ad-
justed for multiple testing. Statistical analyses 
were performed with the use of SAS software, 
version 9.3 (SAS Institute).
R esult s
Baseline and Follow-up Characteristics
Between March 18, 2008, and July 16, 2012, a 
total of 2076 patients were randomly assigned to 
treatment groups; 20 (1%) were subsequently ex-
cluded and 2056 (99%) were included in the 
analyses (Fig. 1). Participants assigned to the de-
ferred-ART strategy were followed for 2382 per-
son-years, and those assigned to the early-ART 
strategy were followed for 2375 person-years 
(Table 1). The rate of attendance at scheduled 
visits was 93% at 3 months and 86% at 30 months 
(Table S1 in Section 6 in the Supplementary Ap-
pendix). At study termination, 47 patients (2%) 
were known to have died, and 58 (3%) were con-
sidered to have been lost to follow-up, with no 
significant differences among the strategies.
Trial Interventions
Among patients assigned to the deferred-ART 
strategy, the 30-month probability of starting 
ART was 63% (Fig. S1 in Section 7 in the Supple-
mentary Appendix). Among the 1033 patients 
assigned to the early-ART strategy, 911 had a 
viral-load measurement after 12 months, of 
whom 84% had an undetectable viral load, and 
872 had a viral-load measurement after 24 
months, of whom 83% had an undetectable viral 
load. Among the 391 patients assigned to de-
ferred ART who started ART more than 12 
months before the 30-month visit, 331 had a 
viral-load measurement after 12 months of ART, 
of whom 80% had an undetectable viral load. 
Among the 70 patients assigned to deferred ART 
who started ART more than 24 months before 
the 30-month visit, 63 had a viral-load measure-
ment after 12 months of ART, of whom 81% had 
an undetectable viral load. Of the 1030 patients 
assigned to the IPT strategy, 927 (90%) actually 
started isoniazid, of whom 94% completed the 
6-month treatment period (Table 1).
Evolution of CD4+ Counts
Among patients assigned to the early-ART strat-
egy, the mean CD4+ count increased from 481 
cells per cubic millimeter at baseline to 728 cells 
per cubic millimeter at 30 months. Among pa-
tients assigned to the deferred-ART strategy, the 
mean CD4+ count decreased from 472 cells per 
cubic millimeter at baseline to 428 cells per cu-
bic millimeter at 12 months and then increased 
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to 511 cells per cubic millimeter at 30 months 
(Fig. S2, S3, and S4 in Section 7 in the Supple-
mentary Appendix). The evolution of the CD4+ 
count did not differ significantly between pa-
tients assigned to IPT and those assigned to no 
IPT. On average, patients had CD4+ counts of at 
least 500 cells per cubic millimeter during 51% 
of their follow-up time (Fig. S5 in Section 7 in 
the Supplementary Appendix).
Primary End Point and Its Components
During follow-up, 204 primary end-point events 
were recorded in 175 patients. With all groups 
considered together, the overall rate of the pri-
mary end point was 3.8 events per 100 person-
years (95% confidence interval [CI], 3.3 to 4.4), 
and the CD4+-specific rates of the primary end 
point for the time during which patients had 
CD4+ counts of at least 500 cells per cubic mil-
Figure 1. Randomization, Study Treatments, and Follow-up.
Clinical indication to start antiretroviral therapy (ART) was irrespective of the CD4+ count. Of the 20 patients who underwent random-
ization but were excluded from analysis, 15 were infected only with human immunodeficiency virus (HIV) type 2 (HIV-2) on HIV tests 
performed at inclusion (these patients were previously thought to have had dual infection with HIV-1 and HIV-2 on the basis of tests 
performed locally), 4 were HIV-seronegative on tests performed at inclusion (these patients were previously found to be HIV-positive lo-
cally and were followed in HIV clinics for 76, 95, 148, and 306 days, respectively, before inclusion), and 1 had a history of combined ART 
that was discovered after inclusion. IPT denotes isoniazid preventive therapy.
2076 Underwent randomization
2962 Patients were screened
886 Were excluded
451 Declined to participate
3 Were pregnant
48 Had clinical indication to start ART
261 Had CD4+ count below range for inclusion
88 Had CD4+ count above range for inclusion
2 Were already receiving ART
33 Had other reasons
520 Were assigned to early
ART (group 3)
 5 Were excluded early
owing to being
HIV-2–positive
515 Received ART
521 Were assigned to early
ART+IPT (group 4)
3 Were excluded early
owing to being
HIV-2–positive
518 Received ART
466 Received IPT
518 Were assigned to deferred
ART (group 1)
517 Were assigned to deferred
ART+IPT (group 2)
18 Were lost to follow-up
13 Were lost to follow-up
29 Discontinued IPT
17 Were lost to follow-up
10 Were lost to follow-up
30 Discontinued IPT
515 Were included in the analysis
5 (1.0%) Were excluded from
the analysis
518 Were included in the analysis
3 (0.6%) Were excluded from
the analysis
511 Were included in the analysis
7 (1.4%) Were excluded from
the analysis
512 Were included in the analysis
5 (1.0%) Were excluded from
the analysis
5 Were excluded early
4 Were HIV-2–positive
1 Was HIV-negative
7 Were excluded early
3 Were HIV-2–positive
3 Were HIV-negative
1 Had previously
received combined
ART
304 Received ART
461 Received IPT
293 Received ART
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Characteristic
Group 1: 
Deferred ART 
(N = 511)
Group 2: 
Deferred ART 
plus IPT 
(N = 512)
Group 3: 
Early ART 
(N = 515)
Group 4: 
Early ART 
plus IPT 
(N = 518)
Baseline
Female sex — no. (%) 400 (78) 391 (76) 407 (79) 416 (80)
Age — yr
Median 35 35 35 35
Interquartile range 29–41 30–42 30–42 29–42
Educational level — no. (%)
Primary school or less 275 (54) 270 (53) 282 (55) 287 (55)
Secondary school or more 236 (46) 242 (47) 233 (45) 231 (45)
WHO clinical stage of HIV infection — no. (%)
1 340 (67) 326 (64) 333 (65) 322 (62)
2 126 (25) 134 (26) 132 (26) 145 (28)
≥3 45 (9) 52 (10) 50 (10) 51 (10)
CD4+ count — cells/mm3
Median 460 459 467 466
Interquartile range 359–560 364–575 369–584 394–572
CD4+ count stratum — no. (%)
≥500 cells/mm3 201 (39) 212 (41) 222 (43) 214 (41)
350–499 cells/mm3 189 (37) 193 (38) 188 (37) 211 (41)
<350 cells/mm3 121 (24) 107 (21) 105 (20) 93 (18)
Plasma HIV-1 RNA — log10 copies/ml
Median 4.6 4.6 4.7 4.7
Interquartile range 4.0–5.2 4.0–5.3 4.0–5.3 4.0–5.3
Dual infection with HIV-1 and HIV-2 — no. (%) 10 (2) 12 (2) 15 (3) 14 (3)
Creatinine clearance <50 ml/min — no. (%) 6 (1) 9 (2) 4 (1) 9 (2)
Plasma alanine aminotransferase >2.5 ×ULN — no. (%) 1 (<0.5) 4 (1) 3 (1) 2 (<0.5)
Hemoglobin <95 g/liter — no. (%) 52 (10) 48 (9) 64 (12) 54 (10)
Positive test for hepatitis B surface antigen — no. (%) 42 (8) 48 (9) 49 (10) 54 (10)
Positive IGRA for tuberculosis — no./total no. (%)† 89/244 (36) 88/241 (37) 84/241 (35) 76/241 (32)
Follow-up
Duration of follow-up — mo
Median 29.9 29.9 29.9 29.9
Interquartile range 29.9–30.0 29.9–30.0 29.9–30.0 29.9–30.0
Lost to follow-up — no. (%) 17 (3) 10 (2) 18 (3) 13 (3)
Total duration of follow-up — patient-yr 1168 1213 1177 1199
Ever started trimethoprim–sulfamethoxazole — no. (%) 467 (91) 476 (93) 451 (88) 455 (88)
Ever started ART — no. (%) 293 (57) 304 (59) 515 (100) 518 (100)
First-line ART regimen — no./total no. (%)
TDF–FTC plus EFV 205/293 (70) 216/304 (71) 362/515 (70) 354/518 (68)
TDF–FTC plus LPV/r‡ 70/293 (24) 68/304 (22) 115/515 (22) 124/518 (24)
Other§ 18/293 (6) 20/304 (7) 38/515 (7) 40/518 (8)
Table 1. Baseline and Follow-up Characteristics.*
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limeter, between 350 and 499 cells per cubic 
millimeter, and less than 350 cells per cubic 
millimeter were 2.8 events per 100 person-years 
(95% CI, 2.1 to 3.5), 4.1 events per 100 person-
years (95% CI, 3.0 to 5.1), and 6.8 events per 100 
person-years (95% CI, 5.0 to 8.6), respectively 
(Fig. S6 in Section 7 in the Supplementary Ap-
pendix).
The mean (±SD) CD4+ count at the onset of a 
first primary end-point event was 414±162 cells 
per cubic millimeter among patients assigned to 
the deferred-ART strategy and 547±239 cells per 
cubic millimeter among patients assigned to the 
early-ART strategy. The 30-month probability of 
a primary end-point event was 11.4% among 
patients assigned to the deferred-ART strategy, 
6.6% among patients assigned to the early-ART 
strategy, 10.7% among patients assigned to the 
no-IPT strategy, and 7.2% among patients as-
signed to the IPT strategy (Fig. S7 in Section 7 
in the Supplementary Appendix). Probabilities 
according to treatment group are shown in Fig-
ure 2. The hazard ratio for a primary end-point 
event was 0.56 (95% CI, 0.41 to 0.76) with early 
ART as compared with deferred ART (Fig. 3) and 
0.65 (95% CI, 0.48 to 0.88) with IPT as compared 
with no IPT (Fig. 4). There was no significant 
interaction among the strategies (P = 0.45). These 
findings were robust to adjustment for baseline 
CD4+ count, the exclusion of patients enrolled 
before December 2009, the censoring of follow-
up data at the time a first CD4+ count of less 
than 350 cells per cubic millimeter was mea-
sured, consideration of only events classified as 
definite, consideration of each end-point compo-
nent separately, and stratification according to 
baseline CD4+ count, as well as in an analysis in 
which patients with missing data were catego-
rized as having treatment failure and a per-pro-
tocol analysis (Fig. 3 and 4, and Table S6 in 
Section 6 in the Supplementary Appendix).
The primary end-point component that oc-
curred most frequently was tuberculosis (42%), 
followed by invasive bacterial diseases (27%), death 
from any cause (23%), AIDS-defining or non–
AIDS-defining cancers (4%), and other AIDS-de-
fining diseases (3%) Table 2). Drug-sensitivity 
testing was performed in 40 of the 41 patients 
with culture-confirmed tuberculosis: 4 had multi-
drug-resistant tuberculosis (1 had been assigned 
to the IPT strategy, and 3 had been assigned to 
the no-IPT strategy), 5 had isoniazid monoresis-
tance (3 had been assigned to the IPT strategy, 
and 2 had been assigned to the no-IPT strategy), 
and 5 had another resistance profile (1 had been 
assigned to the IPT strategy, and 4 had been as-
signed to the no-IPT strategy). Of the 967 pa-
tients who had a serum test for tuberculosis, 597 
Characteristic
Group 1: 
Deferred ART 
(N = 511)
Group 2: 
Deferred ART 
plus IPT 
(N = 512)
Group 3: 
Early ART 
(N = 515)
Group 4: 
Early ART 
plus IPT 
(N = 518)
Ever started IPT — no. (%)¶ 0 461 (90) 0 466 (90)
Completed 6-mo course of IPT — no./total no. (%)‖ 431/461 (93) 437/466 (94)
*  None of the baseline characteristics differed significantly among the groups. ART denotes antiretroviral therapy, EFV efavirenz, FTC emtric-
itabine, HIV-1 human immunodeficiency virus type 1, IPT isoniazid preventive therapy, LPV/r lopinavir/ritonavir, TDF tenofovir, ULN upper 
limit of the normal range, and WHO World Health Organization.
†  The first 967 enrolled patients underwent an interferon-gamma release assay (IGRA) for tuberculosis (QuantiFERON-TB Gold test, Celestis).
‡  Among the 377 patients who started ART with TDF–FTC plus LPV/r, the reason for not receiving an EFV-based regimen was dual infection 
with HIV-1 and HIV type 2 (15 patients), a history of prevention of mother-to-child transmission with nevirapine (38), declining to use effec-
tive contraception (308), and other reasons (16).
§  Other regimens were TDF–FTC–zidovudine (ZDV) (81 patients), ZDV–lamivudine (3TC)–LPV/r (25), ZDV–3TC–EFV (3), ZDV–3TC–nevirap-
ine (3), didanosine–3TC–EFV (1), stavudine (D4T)–3TC–EFV (1), D4T–3TC–LPV/r (1), and 3TC–abacavir–LPV/r (1).
¶  The reasons for not starting IPT at 1 month were the presence of signs suggestive of tuberculosis on the chest radiograph obtained at base-
line (16 patients), the presence of clinical signs suggestive of tuberculosis at the 1-month visit (47), nonattendance at the 1-month visit 
(24), elevated aminotransferase levels at baseline (6), pregnancy (4), death before 1 month (1), and other reasons (5).
‖  The reasons for stopping IPT prematurely were death from an unknown cause (1 patient), discontinuation by patients for personal, non-
medical reasons (22), discontinuation by physicians because of the presence in the patient of signs or symptoms suggestive of tuberculosis 
(10, of whom 3 were confirmed to have tuberculosis), pregnancy (13), and the following 12 adverse events: elevated aminotransferase levels 
(two grade 2 events, two grade 3 events, and two grade 4 events), psychiatric side effects (two grade 2 events and two grade 3 events), and 
pruritus (two grade 2 events). None of the episodes of elevated aminotransferase levels led to death.
Table 1. (Continued.)
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had a negative test, 337 had a positive test, and 
33 had an indeterminate test result. Of the 597 
patients with a negative test, 16 went on to have 
tuberculosis. Of the 337 patients with a positive 
test, 26 went on to have tuberculosis. Among 
patients with a positive test, those who were as-
signed to IPT had significantly fewer tuberculo-
sis events than those assigned to no IPT (ad-
justed hazard ratio, 0.43; 95% CI, 0.19 to 0.99). 
Among patients with a negative test, those who 
were assigned to IPT also had fewer tuberculosis 
events than those assigned to no IPT, but the 
difference was not significant (adjusted hazard 
ratio, 0.58; 95% CI, 0.21 to 1.61).
Grade 3 or 4 Adverse Events
During follow-up, 165 grade 3 or 4 events were 
recorded in 144 patients (Table 2). The cumula-
tive probability of a grade 3 or 4 event over a 
30-month period was 7.7% among patients as-
signed to the deferred-ART strategy, 7.1% among 
patients assigned to the early-ART strategy, 8.2% 
among patients assigned to the no-IPT strategy, 
and 6.6% among patients assigned to the IPT 
strategy (Fig. S7 in Section 7 in the Supplemen-
tary Appendix). The risk of grade 3 or 4 events 
was 2.6 times as high among patients assigned 
to early ART as among patients assigned to de-
ferred ART during the first 6 months and 2.1 
times as low among patients assigned to early 
ART as among patients assigned to deferred 
ART thereafter. The risk of grade 3 or 4 events 
did not differ significantly between patients as-
signed to IPT and those assigned to no IPT 
(Fig. 4).
Participants with a Baseline CD4+ Count  
of at Least 500 Cells per Cubic Millimeter
A total of 849 patients had a CD4+ count of at 
least 500 cells per cubic millimeter at baseline. 
Among patients with these baseline CD4+ 
counts who were assigned to the deferred-ART 
strategy, the cumulative 30-month probability of 
starting ART was 41% (Fig. S1 in Section 7 in 
the Supplementary Appendix); the mean CD4+ 
count decreased from 617 cells per cubic milli-
meter at baseline to 533 cells per cubic millime-
ter at 6 months and then remained stable. 
Among patients with baseline CD4+ counts of at 
least 500 cells per cubic millimeter who were 
assigned to the early-ART strategy, the mean 
CD4+ count increased from 617 cells per cubic 
millimeter at baseline to 810 cells per cubic mil-
limeter at 30 months (Fig. S4A in Section 7 in 
the Supplementary Appendix). On average, pa-
tients had CD4+ counts of at least 500 cells per 
cubic millimeter during 77% of their follow-up 
time (Fig. S5 in Section 7 in the Supplementary 
Appendix). During follow-up, 68 primary end-
point events were recorded in 61 patients (3.2 
events per 100 person-years; 95% CI, 2.4 to 4.0). 
The mean CD4+ count at the onset of a first 
primary end-point event was 542±144 cells per 
cubic millimeter among patients assigned to 
deferred ART and 702±287 cells per cubic mil-
limeter among patients assigned to early ART. 
The hazard ratio for a primary end-point event 
was 0.56 (95% CI, 0.33 to 0.94) with early ART 
versus deferred ART (Fig. 3) and 0.61 (95% CI, 
0.36 to 1.01) with IPT versus no IPT (P = 0.78 for 
interaction) (Fig. 4).
Discussion
In this study, we recruited 2056 HIV-infected 
adults who were not eligible to start ART at the 
time of enrollment according to the current 
WHO guidelines, in a West African country in 
which IPT is not recommended. Participants had 
baseline CD4+ counts evenly distributed on both 
sides of the CD4+ threshold of 500 cells per 
cubic millimeter. The early initiation of ART and 
6 months of IPT independently resulted in a risk 
of severe HIV-related illness that was 44% lower 
and a risk of death from any cause that was 35% 
lower than the risks with deferred initiation of 
ART and no IPT. The results were robust across 
alternate end-point definitions and CD4+ count 
strata. They were driven mainly by the efficacy 
of both interventions in preventing tuberculosis; 
the efficacy of ART in reducing invasive bacte-
rial diseases also played a role.
Figure 2 (facing page). Kaplan–Meier Curves of Proba-
bility of the Primary End Point and Main Secondary 
End Point.
The primary end point was a composite of death from 
any cause, AIDS-defining disease, non–AIDS-defining 
cancer, or non–AIDS-defining invasive bacterial dis-
ease. The main secondary end point was events of 
grade 3 or 4 according to the grading table for severe 
adverse events of the French National Agency for Re-
search on AIDS and Viral Hepatitis. I bars represent 
95% confidence intervals.
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Our findings suggest that starting ART be-
fore the CD4+ count falls below 500 cells per 
cubic millimeter may be beneficial in patients 
who live in countries that have a high burden of 
tuberculosis and bacterial diseases. The efficacy 
of earlier ART in decreasing the relative risk of 
severe illness, as estimated by hazard ratios, was 
similar when CD4+ counts were above and when 
they were below 500 cells per cubic millimeter, 
and although the absolute risk of events across 
CD4+ categories, as estimated by CD4+-specific 
rates, decreased with increasing CD4+ counts, 
the risk of events remained clinically significant 
during the follow-up time when patients had 
CD4+ counts of at least 500 cells per cubic mil-
limeter. These findings, in patients with CD4+ 
counts of less than 800 cells per cubic millime-
ter, confirm and extend those of the HIV Preven-
tion Trials Network 052 study, which showed 
similar results in patients with CD4+ counts of 
350 to 550 cells per cubic millimeter.25
Despite WHO recommendations,22 many 
countries with a high tuberculosis burden have 
not adopted IPT guidelines. In those that have, 
the coverage remains low.26,27 Previous evidence 
of IPT efficacy from randomized trials was de-
rived mostly from studies conducted before the 
ART era.22,28-31 Evidence for the added value of 
IPT in patients receiving ART was mostly from 
patients with CD4+ counts of less than 500 cells 
per cubic millimeter.32-38 Our data are consistent 
with these previous studies that showed that IPT 
and ART have additive efficacy with respect to 
the prevention of tuberculosis and that suggest-
ed that the two therapies should be given con-
comitantly. They also highlight for countries 
that are reluctant to recommend IPT that isonia-
zid can be prescribed safely when given early in 
the course of HIV disease.
Short-term adverse events were more com-
mon with earlier ART than with deferred ART 
and involved toxic effects that are expected with 
antiretroviral drugs — mainly digestive and 
neurologic effects. The cumulative numbers of 
other primary end-point components, including 
AIDS-defining and non–AIDS-defining cancers, 
and of other grade 3 or 4 events, including he-
matologic, renal, and hepatic events, were high-
er among patients assigned to the deferred-ART 
strategy.
Our study has several limitations. First, the 
frequency of events such as cancers, cardiovas-
cular diseases, or bone-related toxic effects was 
probably underestimated, owing to limited diag-
nostic techniques. Second, this was an open-label 
study in which investigators were aware of the 
trial interventions. Third, during the study peri-
od, we adapted our criteria for starting ART in 
patients assigned to the deferred-ART strategy 
as WHO guidelines evolved. Therefore, the early-
ART strategy was not compared with a single, 
unchanging reference strategy. This is both a 
limitation and a strength of the study, because it 
allowed an assessment of the efficacy of the in-
terventions as practice changed. Our data high-
light the continued benefit of starting ART ear-
lier than at the CD4+ thresholds recommended 
by the WHO, even though the threshold was 
raised over time to 500 cells per cubic millime-
ter. The robustness of our results in patients 
with CD4+ counts of at least 500 cells per cubic 
millimeter suggests that the true effective treat-
ment threshold, if there is any, is at least 800 
cells per cubic millimeter.
Finally, although our findings suggest that 
earlier initiation of ART than is currently recom-
mended in Ivory Coast may be beneficial, they 
do not answer the question of whether higher 
CD4+ thresholds should be used or whether ART 
should be recommended to all HIV-infected pa-
tients regardless of the CD4+ count. On the one 
hand, tuberculosis and bacterial diseases are 
common diseases that act as opportunistic in-
fections in people living with HIV, and we sus-
pect that there is no higher CD4+ threshold that 
could identify a sharp decrease in risk.39-42 On 
the other hand, patients with slow progression 
of HIV infection, who represent a small minor-
ity of patients, may not have the same benefit–
risk ratio from earlier ART as other patients.
During the trial period, patients who started 
ART early and those who deferred and eventu-
ally started ART had similar rates of loss to 
follow-up, attendance at scheduled visits, and 
virologic success at 24 months. However, all the 
patients who were assigned to the early-ART 
strategy received 30 months of treatment, 
whereas most patients who were assigned to the 
deferred-ART strategy did not. We thus extended 
follow-up for patients assigned to the deferred-
ART strategy who started ART during the course 
of the trial (i.e., within 30 months after inclu-
sion) until they reached 30 months of treatment. 
Further comparison of adherence and virologic 
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Event
Group 1: 
Deferred ART
Group 2: 
Deferred ART 
plus IPT
Group 3: 
Early ART
Group 4: 
Early ART 
plus IPT
Groups 1 
and 2: 
Deferred-ART 
Strategy
Groups 3 
and 4: 
Early-ART 
Strategy
Groups 1 
and 3: 
No-IPT 
Strategy
Groups 2 
and 4: 
IPT Strategy
number of events
Primary end-point events
Total 75 60 41 28 135 69 116 88
Death* 16 10 13 8 26 21 29 18
Tuberculosis† 41 16 17 11 57 28 58 27
Pulmonary 20 4 11 8 24 19 31 12
Extrapulmonary‡ 21 12 6 3 33 9 27 15
Invasive bacterial disease§ 14 28 7 7 42 14 21 35
AIDS-defining or non–AIDS-
defining cancer¶
1 5 1 2 6 3 2 7
Others AIDS-defining disease¶ 3 1 3 0 4 3 6 1
Grade 3 or 4 adverse events‖
Total 46 44 42 33 90 75 88 77
Hematologic 26 19 16 10 45 26 42 29
Liver-related 8 7 5 5 15 10 13 12
Renal 5 7 0 1 12 1 5 8
Digestive 0 2 8 9 2 17 8 11
Neurologic 2 3 10 3 5 13 12 6
Cardiovascular 2 4 1 2 6 3 3 6
Cutaneous 1 0 2 1 1 3 3 1
Other 2 2 0 2 4 2 2 4
*  Of the 47 deaths, 22 were considered to be of unknown cause; in the case of 25 deaths, a possible or probable cause of death was identi-
fied. Of the latter, 15 were incident events (the main criterion for diagnosing the disease appeared after the patient’s enrollment in the 
study), and 10 were prevalent events (the main criterion for diagnosing the disease was proved to have been present at the time of enroll-
ment). The 15 incident events that were considered to be a possible or probable cause of death were 5 events of tuberculosis, 2 events of 
hepatitis, and 1 event each of stroke, necrotizing fasciitis, visceral abscess, lymphoma, non–AIDS-defining cancer, cryptococcosis, renal in-
sufficiency, and firearm injury. The 10 prevalent events that were considered to be a possible or probable cause of death were 3 events of tuber-
culosis, 3 events of non–AIDS-defining cancer, 2 events of renal insufficiency, and 1 event each of bacterial pneumonia and myocardiopathy.
†  Of the 85 episodes of tuberculosis, 44 were documented as definite (41 with positive cultures and 5 with histologic evidence, including  
2 with positive cultures), 29 as probable, and 12 as possible.
‡  The 42 extrapulmonary cases included 16 cases with both pulmonary and extrapulmonary sites. Documented extrapulmonary disorders 
were deep lymphadenopathy (16 cases), peripheral lymphadenopathy (9), pleural effusion (8), osteomyelitis (4), miliary disease (2), menin-
gitis (1), pericarditis (1), esophageal ulceration (1), mammary gland infection (1), and pancytopenia (1); several disorders could occur in 
the same patient.
§  Of the 56 episodes of invasive bacterial diseases, 30 were documented as definite and 26 as probable. The 56 episodes of invasive bacterial 
diseases were 23 episodes of pneumonia, 12 of isolated bacteremia, 9 of pyelonephritis, 4 of typhoid fever, 2 of prostatitis, 2 of necrotizing 
fasciitis, 2 of enteritis with bacteremia, 1 of visceral abscess, and 1 of septic shock (for details according to trial group and strategy, see 
Table S2 in Section 6 in the Supplementary Appendix). Clinically significant bacteria were isolated in 30 episodes, including 18 from blood 
cultures, 3 from blood and urine cultures, 1 from blood and stool cultures, and 8 from urine cultures. Pathogens were Escherichia coli (15 
episodes), non-Typhi salmonella (6), Salmonella enterica serovar Typhi (4), Klebsiella pneumoniae (2), Streptococcus pneumoniae (1), citrobac-
ter species (1), and acinetobacter species (1).
¶  AIDS-defining diseases were identified as diseases included in the Centers for Disease Control and Prevention case definition of AIDS.7 
Details on the specific disease events are provided in Table S2 in Section 6 in the Supplementary Appendix.
‖  Adverse events were categorized according to the grading table for severe adverse events of the French National Agency for Research on 
AIDS and Viral Hepatitis. Details on the specific events are provided in Table S3 in Section 6 in the Supplementary Appendix.
Table 2. Primary End-Point Events and Grade 3 or 4 Adverse Events, According to Trial Group and Strategy.
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outcomes over a 30-month period of effective 
treatment will provide additional insights.
In conclusion, our findings suggest that ART 
has a favorable benefit–risk ratio in patients be-
fore the CD4+ count reaches the current treat-
ment threshold of 500 cells per cubic millimeter; 
we found that 6 months of IPT combined with 
early ART led to improved outcomes and that the 
spectrum of diseases for which early ART has a 
protective effect includes not only tuberculosis 
but also invasive bacterial diseases. Our data 
suggest that in low-resource settings, ART pro-
vides substantial clinical benefits in patients 
who have higher CD4+ counts at the time of 
initiation than those previously recommended 
for the initiation of ART.
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